Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prelude Therapeutics Inc (NQ: PRLD )

0.9713 +0.0113 (+1.18%)
Streaming Delayed Price Updated: 12:53 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Inc

< Previous 1 2 3 4 Next >
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 150 companies set new 52-week lows. 
Via Benzinga
Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
Expert Ratings for Prelude Therapeutics
Via Benzinga
Analyst Ratings for Prelude Therapeutics
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
Prelude Therapeutics To Participate in Jefferies Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Prelude Therapeutics Announces Pricing of Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Launch of Proposed Public Offering
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference
Eight Abstracts Demonstrate Progress of Prelude’s Differentiated Pipeline 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
The 7 Worst Stocks to Buy Now
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Carvana, Crocs And Other Big Losers From Monday
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
Via Benzinga
Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock
Shares of Prelude Therapeutics Inc (NASDAQ: PRLD) came under pressure during early trading on Monday. 
Via Benzinga
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining more than 250 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
Phase 1 Study Will Include Biomarker Selected Patients with Advanced Solid Tumors 
From Prelude Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
68 Biggest Movers From Yesterday
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.